Hi, you are logged in as , if you are not , please click here
You are shopping as , if this is not your email, please click here

Cancer Research UK & UCL Cancer Trials Centre (H01)

Cancer Inst

The Cancer Research UK and UCL Cancer Trials Centre (CTC) is one of the largest dedicated cancer trials units in the UK. It was formed in 1997, and is now a research department within the UCL Cancer Institute. The CTC develops and conducts high quality studies to find new ways of treating or detecting cancer, and understanding mechanisms of how cancer develops. It has established collaborations with clinicians and scientists, nationally and internationally, to generate new scientific research proposals, develop laboratory projects associated with CTC studies, and train a new generation of clinical trials specialists.

Studies are conducted in a wide range of tumours, primarily, lung, lymphoma, gastrointestinal, head and neck, gynaecology, brain, and sarcoma. Cancer Research UK provides the main source of core funding, with additional core support from the Lymphoma Research Trust. Individual projects are funded by competitive grants from Cancer Research UK, the Lymphoma Research Trust, the Medical Research Council, NIHR, and major pharmaceutical companies.

FOR ALL QUERIES PLEASE USE THE CONTACT TABS FOUND IN EACH OF THE INDIVIDUAL COURSES/CONFERENCES AND PRODUCTS, PLEASE ONLY CONTACT THE ONLINE STORE DIRECTLY IF YOU ARE EXPERIENCING PAYMENT DIFFICULTIES.

Cancer Research UK & UCL Cancer Trials Centre (H01)

UCL Medical School

H01 Introduction to Cancer Clinical Trials 110324

Description

This session provides a general introduction to cancer clinical trials for staff new to academic cancer studies.

Participants will get an overview on what clinical trials are and how they can have a preventative, curative or palliative aim. The session covers the practical and scientific reasons why we need clinical trials, what are the differences between Phase I, II, II and IV studies and the different methods of randomization. The session also highlights how drug development trials in cancer differ from non-cancer studies and how the new era of targeted therapy and immunotherapy is changing the way cancer trials are designed. 

www.ctc.ucl.ac.uk

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]
Clinical Trials

H01 Running a Trial from Concept to Completion 220424

Description

This session gives an introductory overview of all the steps required to design, set up and complete an academic cancer trial conducted in the hospital setting.

Participants will know what all the organisations and people involved in trials do and what permissions and documents need to be in place at different stages of a trial. The course is of most interest to those new to working in academic cancer clinical trials.  Those currently working in the field who would like to gain an overview of what happens at other stages to the one familiar to them, may also benefit.

This course runs from 10.00 - 13.00

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]
Clinical Trials

H01 Cancer Treatments & Their Side Effects - Compliance & Adverse Event Reporting 170624

Description

This session is a basic introduction to cancer treatments and their most common side effects and adverse reactions. The course provides an overview on cancer surgery, radiotherapy and chemotherapy we well as insights on the mechanisms of action of targeted therapies such as monoclonal antibodies, small inhibitory molecules, CAR-T cell therapy and immune checkpoint inhibitors.

In the second part of the session, participants will learn about the mechanisms of toxicity linked to the different categories of cancer therapy and how these are managed.

This course is not recommended for clinicians.

Please note that this course runs from 10.00-13.00

www.ctc.ucl.ac.uk

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]
Clinical Trials

H01 ATMP Regulations CAR T Manufacturing & Clinical Trial Considerations.

Description

Aims: This half-day provides a comprehensive exploration of Advanced Therapy Medicinal Products (ATMPs) and their regulatory framework. Participants will gain insights into the historical context of ATMP regulations and classifications, as well as delve into topics such as Good Clinical Practice (GCP), safety considerations, CAR T (Chimeric Antigen Receptor T cell) mechanism of action and viral vectors.  The course also focuses on Good Manufacturing Practice (GMP) for ATMPs, covering key considerations, manufacturing processes, and quality control, ultimately allowing participants to gain an understanding in the dynamic field of advanced therapies in the context of clinical trials

www.ctc.ucl.ac.uk

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]
Clinical Trials

H01 Trial Outcomes - What Are We Trying To Measure 040724

Description

This session, aimed at non-statisticians, will cover the most common primary outcomes measures used in early and late phase cancer trials.

Learning Outcomes:

Participants will learn what makes a good outcome measure, how outcomes measures are defined and what data need to be collected to assess the outcome, especially for tumour response assessment and time to event measures such as survival and disease (or progression) free survival.

Please note that this course runs from 10.00-13.00

www.ctc.ucl.ac.uk

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]
Clinical Trials

H01 Entering Patients Into Clinical Trials - Pre-Treatment Screening & Eligibility 160524

Description

This session gives a comprehensive overview of the clinical pathways cancer patients can take to be eventually referred for trial entry. The first part of the session spans across the diagnostic methods and staging of cancer and gives a brief overview of the common tests carried out prior to trial treatment.

In the second part of the session participants will learn about the importance of ensuring only eligible patients enter a trial and how eligibility criteria help to safeguard patients and differ amongst different phases of trials. They will also learn the importance of assessing treatment compliance and how every clinical intervention comes with a different set of challenges in collecting data about patient compliance.

Please note this course runs from 10.00-13.00

www.ctc.ucl.ac.uk

Attendee CategoryCostPlace(s) Available  
1) Attendees From Units Within The ICTM.£0.000[Read More]
2) Attendees From Non-Profit Organisations.£50.000[Read More]
3) Attendees From For-Profit Organisations.£100.000[Read More]

How would you rate your experience today?

How can we contact you?

What could we do better?

   Change Code